Allogeneic "off-the-shelf" (OTS) chimeric antigen receptor T cells (CAR-T cells) hold promise for more accessible CAR-T therapy. Here, we report a novel and simple way to make allogeneic OTS T cells targeting cancer. By engineering T cells with a bispecific T cell engager (BiTE), both TCRαβ and CD3ε expression on the T cell surface are dramatically reduced. BiTE-engineered T (BiTE-T) cells show reduced reaction to TCR stimulation and have low risk of graft-versus-host disease (GvHD) . BiTE-T cells down-regulated CD3ε/TCRαβ on bystander T cells by releasing BiTEs. BiTE-T cells produce much fewer cytokines and are comparable to CAR-T cells on anti-cancer efficacy in xenograft mouse models with pre-existing HLA-mismatched T cells. Co-expressing co-stimulatory factors or T cell-promoting cytokines enhanced BiTE-T cells. Our study suggests CD3ε engagement could be a new strategy for allogeneic T cell therapy worthy of further evaluation.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8919219 | PMC |
| http://dx.doi.org/10.1016/j.omto.2022.02.024 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The FLRT3-UNC5B checkpoint pathway inhibits T cell-based cancer immunotherapies.
Sci Adv
March 2024
NextCure Inc., Beltsville, MD 20705, USA.
Cancers exploit coinhibitory receptors on T cells to escape tumor immunity, and targeting such mechanisms has shown remarkable clinical benefit, but in a limited subset of patients. We hypothesized that cancer cells mimic noncanonical mechanisms of early development such as axon guidance pathways to evade T cell immunity. Using gain-of-function genetic screens, we profiled axon guidance proteins on human T cells and their cognate ligands and identified fibronectin leucine-rich transmembrane protein 3 (FLRT3) as a ligand that inhibits T cell activity.
View Article and Find Full Text PDFLocally secreted BiTEs complement CAR T cells by enhancing killing of antigen heterogeneous solid tumors.
Mol Ther
July 2022
Center for Cellular Immunotherapies, University of Pennsylvania Philadelphia, PA 19104, USA; GBM Translational Center of Excellence, Abramson Cancer Center, University of Pennsylvania Philadelphia, PA 19104, USA; Department of Neurosurgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA. Electronic address:
Article Synopsis
- Bispecific T cell engagers (BiTEs) are antibodies designed to redirect T cells towards tumors that express specific antigens, showing potential as a therapy for solid tumors like glioblastomas.
- The study focused on certain tumor-associated antigens (EGFR and IL13Rα2) found in glioma tissues and developed multivalent BiTEs to improve targeting and treatment efficacy.
- BiTE-secreting T cells showed better activation and anti-tumor responses compared to CAR T cells, particularly in early phases of treatment in a glioma mouse model, highlighting their strong therapeutic potential for solid tumors.
CD3 engagement as a new strategy for allogeneic "off-the-shelf" T cell therapy.
Mol Ther Oncolytics
March 2022
Department of Blood and Marrow Transplant and Cellular Immunotherapy, Division of Clinical Science, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.
Allogeneic "off-the-shelf" (OTS) chimeric antigen receptor T cells (CAR-T cells) hold promise for more accessible CAR-T therapy. Here, we report a novel and simple way to make allogeneic OTS T cells targeting cancer. By engineering T cells with a bispecific T cell engager (BiTE), both TCRαβ and CD3ε expression on the T cell surface are dramatically reduced.
View Article and Find Full Text PDFTreatment of hepatocellular carcinoma with a GPC3-targeted bispecific T cell engager.
Oncotarget
August 2017
State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
There are limited strategies for the treatment of hepatocellular carcinoma (HCC). In this study, we prepared a Bispecific T cell engager (BiTE) targeting Glypican 3 (GPC3) and CD3. The GPC3/CD3 BiTE was prepared by fusing the single-chain variable fragment (scFv) of the humanized anti-GPC3 antibody (9F2) with the scFv of the anti-CD3 antibody (OKT3).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!